Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation

Department of Cardiology, Tubingen University, Germany.

OBJECTIVES: The specific objective of the REDUCE trial was to evaluate the effect of low molecular weight heparin on the incidence and occurrence of restenosis in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: Unfractionated heparin and its low molecular weight fragments possess antiproliferative effects and have been shown to reduce neointimal smooth muscle cell migration and proliferation in response to vascular injury in experimental studies. METHODS: The REDUCE trial is an international prospective, randomized, double-blind, multicenter study. Twenty-six centers in Europe and Canada enrolled 625 patients with single-lesion coronary artery obstructions suitable for PTCA. Three hundred six patients received reviparin as a 7,000-U bolus before PTCA, followed by 10,500 U as an infusion over 24 h and then twice-daily 3,500-U subcutaneous application for 28 days. The 306 patients in the control group received a bolus of 10,000 U of unfractionated heparin followed by an infusion of 24,000 U over 24 h. These patients then underwent 28 days of subcutaneous placebo injections. The primary end points were efficacy (defined as a reduction in the incidence of major adverse events [i.e., death, myocardial infarction, need for reintervention or bypass surgery]), absolute loss of minimal lumen diameter and incidence of restenosis during the observation period of 30 weeks after PTCA. RESULTS: Using the intention to treat analysis for all patients, 102 (33.3%) in the reviparin group and 98 (32%) in the control group have reached a primary clinical end point (relative risk [RR] 1.04, 95% confidence interval [CI] 0.83 to 1.31, p = 0.707). Likewise, no difference in late loss of minimal lumen diameter was evident for both groups. Acute events within 24 h occurred in 12 patients (3.9%) in the reviparin group and 25 (8.2%) in the control group (RR 0.49, 95% CI 0.26 to 0.92, p = 0.027) during or immediately after the initial procedure. In the control group, eight major bleeding complications occurred, and in the reviparin group, seven were observed within 35 days after PTCA. CONCLUSIONS: Reviparin use during and after coronary angioplasty did not reduce the occurrence of major clinical events or the incidence of angiographic restenosis over 30 weeks.

This article has been cited by other articles:

				G. Montalescot, R. Gallo, H. D. White, M. Cohen, Ph. G. Steg, P. E.G. Aylward, C. Bode, M. Chiariello, S. B. King III, R. A. Harrington, et al. Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention: 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1083 - 1091. [Abstract] [Full Text] [PDF]

				R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430. [Abstract] [Full Text] [PDF]

				J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]

				L. R Moser and J. S Kalus Role of Low-Molecular-Weight Heparin in Invasive Management of Non-ST-Elevation Acute Coronary Syndromes Ann. Pharmacother., December 1, 2004; 38(12): 2094 - 2104. [Abstract] [Full Text] [PDF]

				J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]

				J R S Day, I S Malik, A Weerasinghe, M Poullis, I Nadra, D O Haskard, K M Taylor, and R C Landis Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention Heart, July 1, 2004; 90(7): 794 - 799. [Abstract] [Full Text] [PDF]

				H.-P. Bestehorn, F.-J. Neumann, H. J. Buttner, P. Betz, P. Sturzenhofecker, E. von Hodenberg, A. Verdun, L. Levai, J. P. Monassier, and H. Roskamm Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2160 - 2165. [Abstract] [Full Text] [PDF]

				G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): e37 - e37. [Abstract] [Full Text] [PDF]

				D. J. Moliterno, J. B. Hermiller, D. J. Kereiakes, E. Yow, R. J. Applegate, G. A. Braden, E. J. Dippel, M. I. Furman, C. L. Grines, N. S. Kleiman, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1132 - 1139. [Abstract] [Full Text] [PDF]

				G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]

				R.e. Choussat, G. Montalescot, J. P. Collet, E. Vicaut, A. Ankri, V. Gallois, G.e. Drobinski, I. Sotirov, and D. Thomas A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1943 - 1950. [Abstract] [Full Text] [PDF]

				P. Kujath, C. Eckmann, and F. Misselwitz Low-Molecular-Weight Heparin in Arterial Reconstructive Surgery: A Double-Blind, Randomized Dose-Finding Trial Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 337 - 345. [Abstract] [PDF]

				G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]

				J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris Circulation, February 6, 2001; 103(5): 658 - 663. [Abstract] [Full Text] [PDF]

				G. G Nenci and A. Minciotti Low molecular weight heparins for arterial thrombosis Vascular Medicine, November 1, 2000; 5(4): 251 - 258. [Abstract] [PDF]

				N Meneveau, F Schiele, G Grollier, B Farah, J.M Lablanche, K Khalife, J Machecourt, N Danchin, J.E Wolf, M Simpson, et al. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS Trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study Eur. Heart J., November 1, 2000; 21(21): 1767 - 1775. [Abstract] [PDF]

				S. Kageyama, H. Yamamoto, and R. Yoshimoto Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2303 - 2308. [Abstract] [Full Text] [PDF]

				D. S Ettenson and E. R Edelman Local drug delivery: an emerging approach in the treatment of restenosis Vascular Medicine, May 1, 2000; 5(2): 97 - 102. [Abstract] [PDF]

				D. M Templeton, Y. Zhao, and M. Y. Fan Heterogeneity in the response of vascular smooth muscle to heparin: altered signaling in heparin-resistant cells Cardiovasc Res, January 14, 2000; 45(2): 503 - 512. [Abstract] [Full Text] [PDF]

				W.-m. Cheung, M. R. D’Andrea, P. Andrade-Gordon, and B. P. Damiano Altered Vascular Injury Responses in Mice Deficient in Protease-Activated Receptor-1 Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 3014 - 3024. [Abstract] [Full Text] [PDF]

				A. Betriu, M. Masotti, A. Serra, J. Alonso, F. Fernandez-Aviles, F. Gimeno, T. Colman, J. Zueco, J. L. Delcan, E. Garcia, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): A four-year follow-up J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1498 - 1506. [Abstract] [Full Text] [PDF]

				C. E. Hart, L. W. Kraiss, S. Vergel, D. Gilbertson, R. Kenagy, T. Kirkman, D. L. Crandall, S. Tickle, H. Finney, G. Yarranton, et al. PDGFß Receptor Blockade Inhibits Intimal Hyperplasia in the Baboon Circulation, February 2, 1999; 99(4): 564 - 569. [Abstract] [Full Text] [PDF]

				A. Gershlick Endovascular manipulation to restrict restenosis Vascular Medicine, August 1, 1998; 3(3): 177 - 188. [Abstract] [PDF]

				A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]

				J.-M. Lablanche, E. P. McFadden, N. Meneveau, J. R. Lusson, B. Bertrand, J.-P. Metzger, V. Legrand, G. Grollier, C. Macaya, B. de Bruyne, et al. Effect of Nadroparin, a Low-Molecular-Weight Heparin, on Clinical and Angiographic Restenosis After Coronary Balloon Angioplasty : The FACT Study Circulation, November 18, 1997; 96(10): 3396 - 3402. [Abstract] [Full Text]